Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845 | 0.89 | CYP2D6 (0.41) | CYP2D6LMNACYP1A2SCN1ASCN2A | |
| SCHEMBL25331 | 0.85 | GAA (0.39) | CYP2D6LMNACYP1A2SCN1ASCN2A | |
| SCHEMBL25400 | 0.85 | LMNA (0.38) | CYP2D6LMNACYP1A2SCN1ASCN2A | |
| SCHEMBL27055 | 0.84 | CYP2D6 (0.40) | CYP2D6LMNACYP1A2SCN1ASCN2A | |
| SCHEMBL24850 | 0.82 | ALDH1A1 (0.41) | LMNACYP1A2GAAKMT2AALDH1A1 | |
| Gabapentin Enacarbil SCHEMBL977603 | 0.82 | ALDH1A1 (0.41) | LMNACYP1A2GAAKMT2AALDH1A1 | |
| Gabapentin Enacarbil SCHEMBL25455 | 0.82 | ALDH1A1 (0.41) | LMNACYP1A2GAAKMT2AALDH1A1 | |
| SCHEMBL25883 | 0.81 | LMNA (0.41) | CYP2D6LMNACYP1A2SCN1ASCN2A | |
| SCHEMBL4754475 | 0.81 | LMNA (0.42) | CYP2D6LMNACYP1A2SCN1ASCN2A | |
| SCHEMBL25397 | 0.81 | ALDH1A1 (0.40) | LMNACYP1A2GAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9238616-B2 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8367722-B2 | Methods of using prodrugs of pregabalin | XENOPORT, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8168623-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8143437-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120035258-A1 | METHODS OF USING PRODRUGS OF PREGABALIN | XENOPORT, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1902714-B1 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8048917-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20050239725-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6927036-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XERO PORT, INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6818787-B2 | FOR THERAPY AND PROPHYLAXIS OF EPILEPSY, DEPRESSION, ANXIETY, PSYCHOSIS, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, PANIC, PAIN, INFLAMMATORY DISEASE, INSOMNIA, GASTROINTESTINAL DISORDERS | XENOPORT, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2004-01-08 | — | — | US | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
| US-20030171303-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | ARBOR PHARMACEUTICALS, LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | CYP2D6 105/4885LMNA 3012/4885CYP1A2 135/4885 |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | CYP2D6 105/4885LMNA 3012/4885CYP1A2 135/4885 |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CYP2D6 105/4885LMNA 3012/4885CYP1A2 135/4885 |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CYP2D6 105/4885LMNA 3012/4885CYP1A2 135/4885 |
| US-20120035258-A1 | METHODS OF USING PRODRUGS OF PREGABALIN | GABBR1, GABRB2, GABBR2 | CYP2D6 62/4885LMNA 2052/4885CYP1A2 107/4885 |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | CYP2D6 105/4885LMNA 3012/4885CYP1A2 135/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CYP2D6 105/4885LMNA 3012/4885CYP1A2 135/4885 |
| US-20030171303-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | AADAC, UGT1A1, AGPAT5 | CYP2D6 25/4885LMNA 2537/4885CYP1A2 24/4885 |
| US-20050239725-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | AADAC, UGT1A1, ABHD5 | CYP2D6 23/4885LMNA 2708/4885CYP1A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.